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Abstract
Background and Objectives: Complications resulting in hospital readmission are important concerns for those considering
bariatric surgery, yet present understanding of the risk for these events is limited to a small number of patient factors. We
sought to identify demographic characteristics, concomitant morbidities, and perioperative factors associated with hospital
readmission following bariatric surgery.
Methods: We report on a prospective observational study of 24,662 patients undergoing primary RYGB and 26,002 patients
undergoing primary AGB at 249 and 317 Bariatric Surgery Centers of Excellence (BSCOE), respectively, in the United States
from January 2007 to August 2009. Data were collected using standardized assessments of demographic factors and
comorbidities, as well as longitudinal records of hospital readmissions, complications, and mortality.
Results: The readmission rate was 5.8% for RYGB and 1.2% for AGB patients 30 days after discharge. The greatest predictors
for readmission following RYGB were prolonged length of stay (adjusted odds ratio [OR], 2.3; 95% confidence interval [CI],
2.0–2.7), open surgery (OR, 1.8; CI, 1.4–2.2), and pseudotumor cerebri (OR, 1.6; CI, 1.1–2.4). Prolonged length of stay (OR, 2.3;
CI, 1.6–3.3), history of deep venous thrombosis or pulmonary embolism (OR, 2.1; CI, 1.3–3.3), asthma (OR, 1.5; CI, 1.1–2.1),
and obstructive sleep apnea (OR, 1.5; CI, 1.1–1.9) were associated with the greatest increases in readmission risk for AGB.
The 30-day mortality rate was 0.14% for RYGB and 0.02% for AGB.
Conclusion: Readmission rates are low and mortality is very rare following bariatric surgery, but risk for both is significantly higher
after RYGB. Predictors of readmission were disparate for the two procedures. Results do not support excluding patients with certain
comorbidities since any reductions in overall readmission rates would be very small on the absolute risk scale. Future research
should evaluate the efficacy of post-surgical managed care plans for patients at higher risk for readmission and adverse events.
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Introduction
The astonishing rise in obesity prevalence and the marked
decline in perioperative mortality over the previous two decades
have both contributed to the growing popularity of bariatric
surgery. In the period from 1998 to 2003, the number of bariatric
procedures performed increased 10-fold [1], and in 2009 alone,
220,000 bariatric surgeries were performed in the United States
and Canada [2]. Despite the clinical benefits, the potential for
serious and costly major adverse events deters many patients and
payers from utilizing its advantages.
Bariatric surgery is safe with a 0.15% to 0.5% 30-day mortality
rate [3–6], however an appreciable proportion of patients suffer at
least one major adverse event within the first 30 days following
either Roux-en-Y gastric bypass (RYGB) or adjustable gastric
banding (AGB) that results in hospital readmission. A hospital
readmission increases the average 180-day cost of a bariatric
operation from approximately $27,000 to $65,000 [7]. In response
to the high costs of hospital readmission, in 2008 the National
Quality Forum indicated that hospital readmission rates would be
a central factor in evaluating hospital performance with penalties
being levied against hospitals with high readmission rates.
Identifyingpatientandsurgicalfactorsthat increaseperioperative
risk of readmission would improve both the tenability of bariatric
surgery for patients and the cost-effectiveness for payers. Compre-
hensive assessment of patient risks a priori would provide physicians
with a framework for either tailoring the selection of intervention or
identifying patients most in need of enhanced education or
monitoring post-operatively, which could, in turn, reduce the
frequency of readmission following bariatric surgery. We have
utilizedtheBariatricOutcomesLongitudinalDatabase(BOLD),the
largest prospective database of bariatric patient outcomes world-
wide, to identify predictors of serious postoperative complications
requiring hospital readmission within 30 days of discharge.
Methods
Design Overview
We obtained patient data from BOLD collected between
January 1, 2007 and August 31, 2009 at 450 Bariatric Surgery
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overseen by the Surgical Review Corporation (SRC). Written
informed consent was obtained from all patients, and the protocols
of this study were approved by the University of Minnesota
institutional review board.
The American Society for Metabolic and Bariatric Surgery
(ASMBS) founded SRC in 2003 as an independent, nonprofit
research organization to oversee compliance and collect data on
patient outcomes for accredited BSCOE hospitals. The criteria set
forth by the ASMBS for BSCOE certification include: performing
at least 125 bariatric surgeries per year in hospitals or 100 bariatric
surgeries per year in surgery centers; surgeons must have
completed 125 bariatric surgeries during their career and must
continue to perform at least 50 bariatric surgeries per year; a
multidisciplinary staff including a team of nurses, surgeons,
dieticians and other consultants; onsite inspections of BSCOE
must be performed every three years; and, hospitals must report
their outcomes to the BOLD database.
BOLD, an internet-based database implemented in 2007,
represents the largest repository of clinical bariatric patient surgery
information in the world with 521 contributing BSCOE. BOLD
collects standardized assessments of patient demographics, preop-
erative morbidities, medication use, surgical procedures, and post-
surgical follow-up visits. Additional details regarding the opera-
tional procedures of BOLD have been reported previously [8].
Standard protocol for BSCOE requests that patients return to
their operating physician for periodic follow-up visits including at
least one visit one month post-operatively. At each follow-up visit,
visit-specific information is recorded into BOLD on weight,
complications, and readmissions since the previous follow-up visit
regardless of whether the readmitting hospital was BSCOE-
certified.
Setting and Participants
Enrollment and data entry for BOLD is ongoing, though we
excluded surgeries which took place after August 31, 2009 to
ensure that all patients had adequate opportunity to follow-up
with their surgical center and BSCOE had sufficient time to
submit patient data as of the most recent database closing on
March 1, 2010. For each patient in the study, we extracted
complete data on demographic information, comorbidities,
inpatient data, and post-surgical follow-up, including data on
readmissions, complications, and mortality. Self-reported data on
demographics and comorbid conditions were complete for nearly
all patients and suspect data entry errors were rare. Suspect BMI
values were replaced with data from an alternate visit. Patients
were eligible for inclusion if they underwent a non-revision
RYGB or AGB and had complete follow-up through at least 30
days following discharge.
The 30-day follow-up rate among BOLD participants was
91.6% during the study period, however follow-up rates were
variable across BSCOE. Analysis of the within-BSCOE relation-
ship between the follow-up rate and readmission rate indicated
that centers with lower follow-up rates tended to report lower
readmission rates, suggesting that centers with lower follow-up
rates underreported their true readmission rates. To ensure high
accuracy of outcomes reporting, we excluded BSCOE reporting
complete 30-day outcome data for fewer than 90% of their
surgical patients. Statistically significant differences between
patients from included and excluded BSCOE were observed for
several baseline characteristics due to the large sample sizes and
correspondingly small standard errors, but these differences were
small in magnitude and not clinically relevant. Sensitivity analyses
on the effect of restricting participants to highly compliant BSCOE
were performed on the readmission and mortality rates under a
wide variety of assumptions, but had little effect on the rates due to
the relative rarity of the outcome.
Outcomes and Follow-up
Predictors of interest were demographic, health, and surgical
variables. Clinical definitions of comorbid conditions are presented
in Table 1. Prolonged length of stay was defined as a hospital stay
$4 days for laparoscopic RYGB, $6 days for open RYGB and
$2 days for AGB. Our outcome was all-cause hospital
readmission within 30 days of discharge requiring hospitalization
for .23 hours. We considered patients to be at risk for
readmission on the day of discharge. No serious intraoperative
complications requiring additional hospitalization were classified
as readmissions. Patients were considered at risk for mortality on
the day of surgery. Patients who were readmitted and died in the
hospital within 30 days of surgery were classified as both
readmissions and mortalities; patients who died outside a hospital
were classified as mortalities but not readmissions.
Statistical Analysis
The demographic characteristics and medical histories of
patients undergoing the two surgeries were compared with t-tests
for continuous variables and chi-square tests for categorical
variables, and Fisher’s exact tests for rare counts. Risk factors
for readmission were evaluated using a series of generalized linear
mixed-effects models. Demographic, health, and surgical covari-
ates were estimated as fixed effects and a random effect was
estimated for BSCOE to account for variation between and
correlation within BSCOE in their readmission rates. Those
covariates significantly associated with readmission in univariate
analysis at a significance level of 0.10 or greater were entered into
a multivariate model with an iterative backward selection
procedure that continued until all variables were significant at
the 0.10 level.
We used expanded mixed-effects logistic models with interac-
tions to examine mediation of risk factors by surgical approach.
Readmission risk was higher among open surgeries, however the
risk factors for open and laparoscopic RYGB approaches were not
significantly different in the expanded models, so we controlled for
the higher rate of readmission among open procedures with an
additional fixed effect and did not stratify models by surgical
approach. All P values are two-sided and are unadjusted for
multiple comparisons. Statistical analyses were conducted in SAS
version 9.2 (SAS Institute Inc., Cary, North Carolina) and graphs
were generated in R version 2.14.0 (R Development Core Team,
2011).
Results
Patients
Figure 1 details the patient selection process. Among BSCOE
eligible for analysis, 24,662 RYGB patients from 249 BSCOE and
26,002 AGB patients from 317 BSCOE were followed-up at 30
days. Bariatric surgery patients had a mean age of 45.9611.9
years and were predominantly female (78.9%) and Caucasian
(80.1%). Patients undergoing RYGB had higher BMI and higher
prevalence of comorbidities than patients who underwent AGB
(Table 2). The laparoscopic approach was employed for 90.7% of
RYGB and 99.7% of AGB operations. Prior to discharge, 1,728
(7.7%) laparoscopic RYGB patients, 159 (7.0%) open RYGB
patients, and 1,183 AGB patients (4.6%) had a prolonged length of
stay.
Risk for Readmission following Bariatric Surgery
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In the first 30 days after discharge, 1437 (5.8%) RYGB patients
and 322 (1.2%) AGB patients were readmitted (Figure 2; P,0.001
for difference). Patients undergoing RYGB procedures with the
laparoscopic approach had fewer readmissions than patients who
underwent RYGB with an open approach (5.6% v. 7.9%,
P,0.001). The most commonly reported complications at
readmission were nausea/vomiting and dehydration for both
procedures, though more than one reason could be recorded for a
readmission (Table 3). For RYGB, other common complications
at readmission were gastrointestinal bleeding, stricture, and
obstruction; pneumonia, device-related infection, and obstruction
were common complications reported at AGB readmissions.
Within the 30 days of the primary operation, 35 (0.14%) RYGB
patients and 6 (0.02%) AGB patients died (P,0.001 for difference).
For RYGB patients, causes of mortality were sepsis (n=11), cardiac
failure (n=6), myocardial infarction (n=4) respiratory failure
(n=4), stroke (n=2), pulmonary embolus (n=1), or could not be
determined (n=6). For AGB patients, causes of death were
myocardial infarction (n=3) or indeterminate (n=3).
Predictors of readmission
Table 4 presents univariate and multivariate risk factor analyses
for readmission. After adjusting for other significant covariates,
prolonged length of stay more than doubled the odds of
readmission for a RYGB patient and the open surgical approach
nearly doubled odds of readmission. Patients with current
symptoms of clinical depression or psychosocial impairment,
peripheral vascular disease, pseudotumor cerebri, or those with a
previous history of gallstones or cholecystecomy were more likely
to be readmitted than those without those symptoms. The number
of medications used preoperatively was also associated with higher
Table 1. Clinical definitions of pre-existing conditions.
Condition Clinical Definition
Abdominal hernia Any history of symptomatic or asymptomatic abdominal hernia
Abdominal/skin pannus Any current symptoms, including intertriginous irritation, interfering with ambulation, recurrent cellulitis, or ulceration
Alcohol use Any current alcohol use
Angina Any chest pain symptoms or angina regardless of exertion
Asthma Any symptoms of asthma regardless of medication usage
Back pain Has degenerative changes or positive objective findings, symptoms require narcotic treatment
Bipolar disorder Confirmed diagnosis of bipolar disorder
Cholelithiasis Has had gallstones with severe symptoms or has had a cholecystectomy
Congestive heart failure Any history or symptoms of congestive heart failure (Class I, II, III, and IV)
Depression At least moderate depression with significant impairment, undergoing medical or therapeutic treatment
DVT/PE Any history of resolved or recurrent deep venous thrombosis or pulmonary embolism
Fibromyalgia Any degree of fibromyalgia
Gastroesophageal reflux disease Symptoms require the use of medical treatment (at least H2 blockers or low-dose proton pump inhibitor)
Gout/hyperuricemia Has at least symptomatic or asymptomatic hyperuricemia
Hypertension Requires medical treatment with multiple medications
Ischemic heart disease Has at least abnormal electrocardiogram, regardless of active ischemia; may include history of myocardial infarction
Lipids Heightened cholesterol requiring at least single medication
Liver disease Any history of liver disease, including hepatomegaly or non-normal liver function test
Lower extremity edema Has symptoms requiring treatment, diuretics, elevation, or hose
Musculoskeletal disease Has pain with household ambulation, requires surgical intervention, or past joint replacement
Obesity hypoventilation syndrome Any symptoms including hypoxemia or hypercarbia on room air
Obstructive sleep apnea Sleep apnea requiring oral appliance, significant hypoxia, or oxygen-dependent
Panic disorder Confirmed diagnosis of panic disorder
Peripheral vascular disease Any symptoms of peripheral vascular disease
Personality disorder Confirmed diagnosis of personality disorder
Psychosocial impairment Any indicated psychosocial impairment, regardless of ability to perform primary tasks
Pseudotumor cerebri Any symptoms of pseudotumor cerebri (at least headaches with dizziness, nausea, or pain behind the eyes) with or without
visual symptoms
Psychosis Confirmed diagnosis of psychosis
Pulmonary hypertension Any symptoms associated with pulmonary hypertension (shortness of breath, dizziness, fainting)
Substance abuse Any recent substance abuse
Stress urinary incontinence Frequent stress urinary incontinence, regardless of severity
Tobacco use Any recent tobacco use
Type-2 diabetes Diabetes requiring insulin
Abbreviations: DVT, deep venous thrombosis; PE, pulmonary embolism.
doi:10.1371/journal.pone.0032506.t001
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higher odds of readmission compared to a Caucasian individual
holding other factors constant.
For AGB, prolonged length of stay also doubled a patient’s odds
of readmission. Male patients had nearly 50% greater odds of
readmission than female patients, and disabled and retired
employment statuses were more likely to have been readmitted
than employed individuals after controlling for other significant
demographic and health factors. Patients undergoing AGB with
symptomatic asthma, gastroesophageal reflux disease (GERD),
obstructive sleep apnea (OSA), or a history of deep venous
thrombosis or pulmonary embolism (DVT/PE) had significantly
higher odds of being readmitted within 30 days compared to
patients without those medical complications.
Discussion
The overall reduction in mortality and the resolution of chronic
diseases such as type 2 diabetes are substantial following bariatric
surgery [9–15]. However, the potential for serious complications is
a barrier for patients and payers to utilizing the long-term
advantages offered by bariatric surgery. The penalizing of
hospitals for early readmissions is already underway, and several
states are imposing mandates that call for further reductions in
readmissions. Primary care providers and surgeons alike will see
substantial decreases in reimbursements for readmitted patients,
and it is therefore imperative that systems be in place to prevent
the occurrence of readmissions. In this study, we have identified
factors predictive of severe events requiring hospital readmission
within 30 days of RYGB or AGB in the largest prospective
bariatric cohort to date and have established that short-term risk
for readmission is low for both procedures and risk profiles are
largely unique to each procedure.
We observed a RYGB readmission rate nearly five times higher
than AGB. Previously reported hospital readmission rates for
bariatric surgery vary widely in the literature [6,7,16–20]. Possible
explanations for these disparities may be due to differences in the
patient populations, the definition of a hospital readmission, the
Figure 1. Flow diagram of patient selection.
doi:10.1371/journal.pone.0032506.g001
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Roux-en-Y Gastric Bypass Adjustable Gastric Banding
(n=24,662) (n=26,002)
Variable Mean (SD)/No. (%) Mean (SD)/No. (%) P value
a
Demographics
Age 45.7 (11.6) 46.1 (12.1) ,0.001
Female sex 19,259 (78.1) 20,736 (79.8) ,0.001
Black race 2265 (9.2) 2890 (11.1) ,0.001
Caucasian race 19,973 (81.0) 20,590 (79.2) ,0.001
Disabled 2140 (8.7) 1192 (4.6) ,0.001
Private insurance 20,878 (84.7) 21,478 (82.6) ,0.001
Medicare/Medicaid 2919 (11.8) 2148 (8.6) ,0.001
Medical history
BMI
b 47.2 (8.3) 44.2 (6.7) ,0.001
Number of medications 3.8 (4.0) 2.8 (3.5) ,0.001
Comorbidities
Abdominal hernia 1379 (5.6) 1032 (4.0) ,0.001
Abdominal/skin pannus 2097 (8.5) 1081 (4.2) ,0.001
Alcohol use 7469 (30.3) 7194 (27.7) ,0.001
Angina 914 (3.7) 576 (2.2) ,0.001
Asthma 3312 (13.4) 2707 (10.4) ,0.001
Back pain 2629 (10.7) 1926 (7.4) ,0.001
Bipolar disorder 490 (2.0) 350 (1.4) ,0.001
Cholelithiasis 4614 (18.7) 3843 (14.8) ,0.001
Congestive heart failure 703 (2.9) 435 (1.7) ,0.001
Depression 3589 (14.6) 3065 (11.8) ,0.001
DVT/PE 937 (3.8) 850 (3.3) 0.001
Fibromyalgia 908 (3.7) 694 (2.7) ,0.001
GERD 6473 (26.3) 5629 (21.7) ,0.001
Gout/hyperuricemia 1006 (4.1) 644 (2.5) ,0.001
Hypertension 5850 (23.7) 5051 (19.4) ,0.001
Ischemic heart disease 1299 (5.3) 1152 (4.4) ,0.001
Lipids 6750 (27.4) 6015 (23.1) ,0.001
Liver disease 2160 (8.8) 1102 (4.2) ,0.001
Lower extremity edema 3138 (12.7) 2342 (9.0) ,0.001
Musculoskeletal disease 2637 (10.7) 2137 (8.2) ,0.001
Obesity hypoventilation syndrome 578 (2.3) 506 (2.0) 0.002
Obstructive sleep apnea 7424 (30.1) 5811 (22.4) ,0.001
Panic disorder 2073 (8.4) 1520 (5.9) ,0.001
Peripheral vascular disease 327 (1.3) 227 (0.9) ,0.001
Personality disorder 189 (0.8) 59 (0.2) ,0.001
Psychosocial impairment 4321 (17.5) 3040 (11.7) ,0.001
Pseudotumor cerebri 446 (1.8) 278 (1.1) ,0.001
Psychosis 23 (0.1) 15 (0.1) 0.15
Pulmonary hypertension 1430 (5.8) 1051 (4.0) ,0.001
Substance abuse 105 (0.4) 71 (0.3) 0.004
Stress urinary incontinence 2859 (11.6) 2692 (10.4) ,0.001
Tobacco use 1805 (7.3) 1748 (6.7) 0.009
Type-2 diabetes requiring insulin 3029 (12.3) 2030 (7.8) ,0.001
Abbreviations: BSCOE, bariatric surgery center of excellence; DVT, deep venous thrombosis; GERD, gastroesophageal reflux disease; PE, pulmonary embolism.
aP values calculated using t-tests for continuous variables and Pearson’s chi-squared tests or Fisher’s exact tests for categorical variables.
bBody mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.
doi:10.1371/journal.pone.0032506.t002
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laparoscopic procedures, or surgeon experience.
The higher readmission and mortality rates for RYGB relative
to AGB might suggest that AGB is preferable, however such risks
must be weighed with the treatment outcomes. RYGB has been
shown to result in greater weight loss and superior improvement in
comorbid illness [11,21–23]. Our group recently reported on
greater one-year improvements among patients with type 2
diabetes with respect to weight loss, hemoglobin A1C, medication
scores, and rates of diabetes resolution for RYGB patients
compared to matched AGB controls [11]. Short-term complica-
tions must be weighed against the long-term benefits and
complications of each procedure.
The clearest predictors of readmission following RYGB were
the use of the open surgical approach and prolonged length of
stay. While open procedures are justified for certain complex cases
Figure 2. Cumulative incidence of 30-day readmission by surgery.
doi:10.1371/journal.pone.0032506.g002
Table 3. Common Complications at Readmission by Surgery.
Roux-en-Y Gastric Bypass Adjustable Gastric Banding
Most common complications
reported at readmission Complication No. (%) Complication No. (%)
Nausea/vomiting 346 (24.1) Nausea/vomiting 57 (17.7)
Dehydration 170 (11.8) Dehydration 37 (11.5)
Gastrointestinal bleeding 82 (5.7) Device-related infection 27 (8.4)
Stricture 79 (5.5) Device-related obstruction 18 (5.6)
(Internal) obstruction 76 (5.3) Pneumonia 13 (4.0)
Anastomotic leakage 58 (4.0) Wound complication 13 (4.0)
Wound complications 52 (3.6) Device-related intolerance 12 (3.7)
Intra-abdominal abscess 52 (3.6) Deep venous thrombosis 11 (3.4)
30-day readmission rate 1437 (5.8) 322 (1.2)
30-day mortality rate 35 (0.14) 6 (0.02)
BSCOE could report more than one complication at readmission, so the reported percentages reflect the proportion of all readmissions involving those complications.
This table lists the eight most-reported complications per surgery and does not add to 100%. A device-related obstruction was a complication of the device causing
intestinal obstruction, whereas device-related intolerance is an unspecified complication due the device, implant, and graft.
doi:10.1371/journal.pone.0032506.t003
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Roux-en-Y Gastric Bypass Adjustable Gastric Banding
Univariate models Multivariate model Univariate models Multivariate model
Variable OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age (5 years) 1.00 (0.98–1.03) - 1.11 (1.06–1.17) -
Male gender 0.94 (0.83–1.08) - 1.68 (1.32–2.14) 1.45 (1.12–1.87)
Race (ref. Caucasian)
Black/African American 1.32 (1.10–1.58) 1.34 (1.11–1.62) 0.63 (0.41–0.97) -
Hispanic/Latino 1.01 (0.77–1.31) 1.05 (0.81–1.38) 0.97 (0.55–1.70) -
Other 1.06 (0.74–1.51) 1.07 (0.74–1.53) 0.83 (0.44–1.55) -
ASA classification
a (ref. ‘‘1’’)
2/3 – mild systemic disease 1.45 (0.81–2.61) - 1.64 (0.77–3.47) 1.41 (0.66–2.99)
4/5 – severe disease 2.23 (1.20–4.16) - 4.49 (1.88–10.7) 2.44 (1.01–5.89)
BMI
b (ref. 45–49.9)
30–34.9 1.07 (0.71–1.61) - 0.81 (0.42–1.57) -
35–39.9 1.02 (0.86–1.22) - 1.25 (0.88–1.78) -
40–44.9 0.98 (0.84–1.15) - 1.19 (0.84–1.67) -
50–54.9 1.12 (0.94–1.35) - 1.48 (0.96–2.29) -
55–59.9 1.15 (0.91–1.46) - 1.93 (1.11–3.33) -
60+ 1.35 (1.10–1.66) - 2.52 (1.47–4.33) -
Employment status (ref. Employed)
Disabled 1.55 (1.30–1.85) - 2.82 (1.95–4.09) 1.79 (1.21–2.65)
Retired 1.18 (0.96–1.45) - 1.98 (1.43–2.73) 1.43 (1.02–2.01)
Unemployed 1.26 (1.03–1.53) - 1.15 (0.68–1.93) 1.02 (0.60–1.72)
Payment method (ref. private insurance)
Self-payer 0.67 (0.46–0.97) 0.69 (0.48–1.01) 1.10 (0.72–1.69) -
Medicare/Medicaid 1.46 (1.24–1.70) 1.12 (0.95–1.32) 2.22 (1.63–3.03) -
Number of medications (5 med interval) 1.25 (1.17–1.34) 1.10 (1.02–1.19) 1.50 (1.30–1.72) -
Open surgical method 1.93 (1.56–2.39) 1.78 (1.44–2.20) 2.48 (0.59–10.37) -
Prolonged length of stay 2.47 (2.11–2.89) 2.28 (1.95–2.68) 3.08 (2.19–4.33) 2.32 (1.63–3.30)
Comorbidities
Alcohol use 0.76 (0.66–0.87) 0.82 (0.71–0.94) 0.83 (0.63–1.08) -
Angina 1.41 (1.09–1.83) - 2.35 (1.43–3.85) 1.58 (0.95–2.63)
Asthma 1.26 (1.09–1.46) - 1.77 (1.32–2.37) 1.52 (1.12–2.05)
Cholelithiasis 1.29 (1.13–1.48) 1.18 (1.03–1.36) 1.25 (0.93–1.68) -
Depression 1.34 (1.15–1.56) 1.18 (1.01–1.39) 1.18 (0.85–1.65) -
DVT/PE 1.49 (1.17–1.91) 1.24 (0.96–1.60) 2.79 (1.78–4.37) 2.09 (1.32–3.29)
GERD 1.22 (1.08–1.38) - 1.54 (1.20–1.97) 1.30 (1.01–1.68)
Ischemic heart disease 1.49 (1.21–1.83) 1.21 (0.97–1.51) 1.86 (1.24–2.79) -
Lower extremity edema 1.24 (1.06–1.45) - 1.98 (1.45–1.90) 1.36 (0.99–1.89)
Obstructive sleep apnea 1.10 (0.98–1.24) - 1.97 (1.56–2.49) 1.45 (1.13–1.87)
Psychosocial impairment 1.36 (1.17–1.57) 1.19 (1.02–1.39) 0.97 (0.69–1.38) -
Pseudotumor cerebri 1.75 (1.20–2.55) 1.63 (1.11–2.39) 1.82 (0.79–4.22) -
Peripheral vascular disease 1.78 (1.23–2.57) 1.44 (0.99–2.11) 1.28 (0.47–3.50) -
Abbreviations: ASA, American Society of Anesthesiologists; CI, confidence interval; DVT, deep venous thrombosis; GERD, gastroesophageal reflux disease; OR, odds ratio;
PE, pulmonary embolism. Ref denotes the reference group of a categorical variable. The variables for participation of surgical resident, COE volume, abdominal hernia,
abdominal pannus, back pain, bipolar disorder, congestive heart failure, fibromyalgia, gout/hyperuricemia, hypertension, lipids, liver disease, musculoskeletal disease,
obesity hypoventilation syndrome, panic disorder, personality disorder, psychosis, pulmonary hypertension, substance abuse, stress urinary incontinence, and type-2
diabetes were not significant at P#.10 in univariate analysis and/or not significant in either multivariate model for either surgery and are not shown. Dashes indicate
that the variable was not included in the multivariate model because it was removed either for not meeting the significance threshold in the univariate model or for
being removed in the backwards selection procedure.
doi:10.1371/journal.pone.0032506.t004
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Included BSCOE Excluded BSCOE
n=25,877 n=21,664
Variable Mean (SD) or No. (%) Mean (SD) or No. (%) P value
a
BSCOE 249 (55.5) 200 (44.5) -
Age 45.6 (11.6) 45.1 (11.5) ,0.001
Female sex 20,162 (77.9) 17,051 (78.7) 0.04
Race ,0.001
Black 2406 (9.3) 2373 (11.0)
Caucasian 20,909 (80.8) 15,808 (73.0)
Hispanic/Latino 1789 (6.9) 1799 (8.3)
Other 773 (3.0) 1684 (7.8)
ASA Classification ,0.001
1 – normal, healthy 338 (1.3) 1337 (6.2)
2/3 – mild systemic disease 24,072 (93.0) 19,276 (89.0)
4/5 – severe/very severe disease 1467 (5.7) 1051 (4.9)
BMI
b 47.2 (8.3) 47.3 (8.3) 0.37
Employment status ,0.001
Employed 19,879 (76.8) 16,885 (77.9)
Disabled 2273 (8.8) 1680 (7.8)
Retired 1819 (7.0) 1425 (6.6)
Unemployed 1906 (7.4) 1674 (7.7)
Payment Information 0.10
Private insurance 21,876 (84.5) 18,467 (85.2)
Self-payer 903 (3.5) 731 (3.4)
Medicare/Medicaid 3098 (12.0) 2466 (11.4)
Number of medications 3.8 (4.0) 3.2 (3.8) ,0.001
Comorbidities
Abdominal hernia 1456 (5.6) 939 (4.3) ,0.001
Abdominal/skin pannus 2180 (8.4) 1111 (5.1) ,0.001
Alcohol use 7798 (30.1) 6167 (28.5) ,0.001
Angina 976 (3.8) 488 (2.3) ,0.001
Asthma 3477 (13.4) 2903 (13.4) 0.91
Back pain 2754 (10.6) 1982 (9.2) ,0.001
Bipolar disorder 521 (2.0) 446 (2.1) 0.74
Cholelithiasis 4836 (18.7) 3470 (16.0) ,0.001
Congestive heart failure 751 (2.9) 437 (2.0) ,0.001
Depression 3782 (14.6) 2890 (13.3) ,0.001
DVT/PE 971 (3.8) 612 (2.8) ,0.001
Fibromyalgia 949 (3.7) 670 (3.1) ,0.001
GERD 6781 (26.2) 5073 (23.4) ,0.001
Gout/hyperuricemia 1036 (4.0) 655 (3.0) ,0.001
Hypertension 6115 (23.6) 4587 (21.2) ,0.001
Ischemic heart disease 1374 (5.3) 917 (4.2) ,0.001
Lipids 7014 (27.1) 5562 (25.7) ,0.001
Liver disease 2264 (8.8) 1091 (5.0) ,0.001
Lower extremity edema 3287 (12.7) 2370 (10.9) ,0.001
Musculoskeletal disease 2766 (10.7) 2319 (10.7) 0.96
Obesity hypoventilation syndrome 608 (2.4) 525 (2.4) 0.60
Obstructive sleep apnea 7779 (30.1) 6474 (29.9) 0.67
Panic disorder 2175 (8.4) 1483 (6.9) ,0.001
Peripheral vascular disease 247 (1.3) 241 (1.1) 0.02
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suggest that laparoscopic techniques should be preferred to open
surgery in the absence of contraindications for laparoscopy.
Patients with previous histories of bariatric surgery or other
anatomical abnormalities may be best suited for open surgeries
and would understandably be at higher risk for readmission.
However, 7.6% of hospitals (19 of 249 BSCOE) conducted .80%
of their RYGB procedures using the open approach and
accounted for 46.6% of all open procedures in the database,
suggesting that the open approach may be often dictated by
surgeon preference in these hospitals rather than case difficulty.
The influence of serious comorbid disease on readmission risk
for RYGB patients is expected, though the causal pathway of
elevated risk for African-Americans is less clear. We suspect that
the association with race may have been confounded by
unmeasured variables such as surgical preparation, social support,
economic status, or dietary intake. For AGB, readmission risk
factors were quite different from those identified with RYGB with
the exception of prolonged length of stay and severe ASA score:
disability status, asthma, male gender, history of DVT/PE, and
the presence of OSA or GERD.
Surprisingly, the profiles of risk factors for readmission were
almost entirely distinct for the AGB and RYGB procedures.
Prolonged length of stay following surgery was one of the only
factors that significantly predicted readmissions in both surgical
populations in multivariate analysis. That procedure-specific risk
factors contrast so greatly between the two procedures is an
important finding potentially overlooked by prior investigations.
Previous studies have chosen to pool patients across procedures for
analysis assuming that the underlying risk factors were the same
[5,26]. While several of our results are complementary, the choice
to aggregate surgical patients may account for some important
differences in results. Some previous studies examining readmis-
sion rates have identified high BMI as a risk factor for readmission
[5,17], while our own did not. Risk analyses that pooled patients
from multiple procedures may have observed an artificial inflation
of risk for high-BMI patients who tend to undergo RYGB, which
has a significantly higher readmission rate than AGB. The
relationship between BMI and readmission risk may also have
been confounded by a less complete comorbidity profile in risk
models, since many conditions are more prevalent among
individuals of greater weight. The ability to examine the role of
a very extensive list of comorbidities is a major strength of this
analysis.
Many of the identified risk factors, while complex, multifacto-
rial, and often not necessarily modifiable, provide an impetus to
follow patients at higher risk for readmission more aggressively
following discharge. Prolonged length of stay, for example, was
identified as an important risk factor yet the reasons for the longer
stay varied widely in BOLD; both preoperative and perioperative
factors can interact to influence the duration of a patient’s stay.
Despite this heterogeneity, prolonged length of stay could be
utilized as a prompt for enhanced post-discharge monitoring in
patients at higher risk for readmission. Intervention studies are
needed to determine if and how enhanced monitoring, adjunctive
treatments, or additional education might reduce readmission
rates for high-risk patients. Certainly, enhanced monitoring is
unlikely to prevent more serious readmissions such as those in
patients who develop gastrointestinal leaks or obstructions.
Further, it is unknown at this time how much effort would need
to be applied to significantly lower the current readmission rates
that are already acceptably low. However, it may be possible to
impact the most prevalent reasons for readmission, nausea and
vomiting, by establishing infusion centers for patients suffering
from a slow return of bowel function and dehydration.
It is important to recognize the magnitude of relative risk
differences associated with the predictors of readmission in this
analysis; primarily, comorbid conditions must be weighed with the
absolute risk for each procedure. For example, a relative risk of 1.5
for a high-risk patient group compared to a group of typical
patients would equate to an increase of the readmission rate from
5.8% to 8.7% for RYGB and from 1.2% to 1.8% for AGB, or
absolute risk differences of 2.9% and 0.6%, respectively. Patients,
payers, and practitioners alike may find these higher risks
acceptable if outweighed by the benefits of surgery, which are
often greatest among patients with more severe comorbidity
profiles. For these reasons, we deem that the current results do not
support patient selection, but rather highlight patient groups that
could benefit from appropriate preventative or educational efforts,
and possibly, closer post-discharge follow-up.
This study has several limitations. The exclusion of centers with
low follow-up rates is the most important limitation, since it is
Table 5. Cont.
Included BSCOE Excluded BSCOE
n=25,877 n=21,664
Variable Mean (SD) or No. (%) Mean (SD) or No. (%) P value
a
Personality disorder 196 (0.8) 52 (0.2) ,0.001
Psychosocial impairment 4544 (11.6) 3138 (14.5) ,0.001
Pseudotumor cerebri 467 (1.8) 635 (2.9) ,0.001
Psychosis 23 (0.1) 24 (0.1) 0.47
Pulmonary hypertension 1502 (5.8) 727 (3.4) ,0.001
Substance abuse 111 (0.4) 96 (0.4) 0.83
Stress urinary incontinence 2968 (11.5) 2683 (12.4) 0.002
Tobacco use 1910 (7.4) 1447 (6.7) 0.003
Type-2 diabetes 3172 (12.3) 2493 (11.5) 0.01
Abbreviations: BSCOE, bariatric surgery center of excellence; DVT, deep venous thrombosis; GERD, gastroesophageal reflux disease; PE, pulmonary embolism.
aP values calculated using a t-test for continuous variables and Pearson’s chi-squared test or Fisher’s exact test for categorical variables.
bBody mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.
doi:10.1371/journal.pone.0032506.t005
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Included BSCOE Excluded BSCOE
n=26,765 n=8814
Variable Mean (SD) or No. (%) Mean (SD) or No. (%) P value
a
BSCOE 317 (68.3) 147 (31.7) -
Age 46.1 (12.1) 46.5 (12.3) 0.01
Female sex 21,319 (79.7) 6919 (78.5) 0.02
Race ,0.001
Black/African American 2979 (11.1) 942 (10.7)
Caucasian 21,171 (79.1) 6183 (70.2)
Hispanic/Latino 1089 (4.1) 674 (7.7)
Other 1526 (5.7) 1015 (11.5)
ASA Classification 0.004
1 – normal, healthy 1388 (5.2) 381 (4.3)
2/3 – mild systemic disease 24,635 (92.0) 8200 (93.0)
4/5 – severe/very severe disease 742 (2.8) 233 (2.6)
BMI
b 44.2 (6.7) 44.2 (7.2) 0.62
Employment Status ,0.001
Employed 21,937 (82.0) 7132 (80.9)
Disabled 1240 (4.6) 527 (6.0)
Retired 2313 (8.6) 783 (8.9)
Unemployed 1275 (4.8) 372 (4.2)
Payment Information ,0.001
Private Insurance 22,085 (82.5) 7169 (81.3)
Self-Payer 2447 (9.1) 652 (7.4)
Medicare/Medicaid 2233 (8.3) 993 (11.3)
Number of medications 2.8 (3.5) 3.1 (3.5) ,0.001
Comorbidities
Abdominal hernia 1054 (3.9) 486 (5.5) ,0.001
Abdominal/Skin pannus 1107 (4.1) 381 (4.3) 0.44
Alcohol use 7407 (27.7) 2750 (31.2) ,0.001
Angina 596 (2.2) 158 (1.8) 0.01
Asthma 2788 (10.4) 893 (10.1) 0.45
Back pain 1999 (7.5) 626 (7.1) 0.25
Bipolar disorder 364 (1.4) 140 (1.6) 0.12
Cholelithiasis 3938 (14.7) 1146 (13.0) ,0.001
Congestive heart failure 445 (1.7) 140 (1.6) 0.66
Depression 3144 (11.8) 767 (8.7) ,0.001
DVT/PE 878 (3.3) 218 (2.5) ,0.001
Fibromyalgia 708 (2.7) 240 (2.7) 0.70
GERD 5783 (21.6) 1563 (17.7) ,0.001
Gout/hyperuricemia 661 (2.5) 414 (4.7) ,0.001
Hypertension 5197 (19.4) 1693 (19.2) 0.67
Ischemic heart disease 1197 (4.5) 359 (4.1) 0.12
Lipids 6192 (23.1) 2278 (25.9) ,0.001
Liver disease 1151 (4.3) 438 (5.0) 0.008
Lower extremity edema 2413 (9.0) 671 (7.6) ,0.001
Musculoskeletal disease 2219 (8.3) 814 (9.1) 0.02
Obesity hypoventilation syndrome 517 (1.9) 150 (1.7) 0.17
Obstructive sleep apnea 5993 (22.4) 1931 (21.9) 0.34
Panic disorder 1567 (5.9) 541 (6.1) 0.33
Peripheral vascular disease 234 (0.9) 89 (1.0) 0.24
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been the hospitals with the highest readmission rates, as well. Our
sensitivity analyses comparing included and excluded centers did
not indicate that there were substantive clinical differences
between the patient populations (Tables 5 and 6), and if such a
bias were present, it is highly unlikely that an underestimation of
readmission rates would have a considerable impact on the
strength or direction of the risk factors themselves. Long-term
follow-up in BOLD was limited and precluded the examination of
readmissions occurring beyond 30 days. RYGB patients continue
to require readmission up to and beyond one year, and the need
for band revisions generally do not occur within the first 30 days of
Table 6. Cont.
Included BSCOE Excluded BSCOE
n=26,765 n=8814
Variable Mean (SD) or No. (%) Mean (SD) or No. (%) P value
a
Personality disorder 62 (0.2) 10 (0.1) 0.04
Psychosocial impairment 3145 (11.8) 1034 (11.7) 0.96
Pseudotumor cerebri 290 (1.1) 88 (1.0) 0.55
Psychosis 15 (0.1) 6 (0.1) 0.62
Pulmonary hypertension 1084 (4.1) 167 (1.9) ,0.001
Substance abuse 73 (0.3) 35 (0.4) 0.07
Stress urinary incontinence 2748 (10.3) 833 (9.5) 0.03
Tobacco use 1813 (6.8) 568 (6.4) 0.28
Type-2 diabetes 2093 (7.8) 670 (7.6) 0.51
Abbreviations: BSCOE, bariatric surgery center of excellence; DVT, deep venous thrombosis; GERD, gastroesophageal reflux disease; PE, pulmonary embolism.
aP values calculated using a t-test for continuous variables and Pearson’s chi-squared test or Fisher’s exact test for categorical variables.
bBody mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.
doi:10.1371/journal.pone.0032506.t006
Figure 3. Loess plot of RYGB readmission rates on follow-up rates. Circles represent BSCOE hospitals with the size weighted by the number
of patients who underwent the procedure in the hospital during the study period.
doi:10.1371/journal.pone.0032506.g003
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within 30 days [17,18], so the current study likely captures the
most important risk factors for readmission.
The present analysis was also unable to control for surgeon
volume, an important factor in readmission [16,19,20]. however
surgeons reporting to BOLD must log over 50 cases annually in
order to maintain BSCOE certification. Also, the distribution of
readmission rates was not consistent with a uniform rate across
centers (Figures 3 and 4). An appreciable number of BSCOE,
for AGB in particular, reported readmission rates considerably
lower than would be expected under a constant rate across
centers of varying surgical volume. We suspect that unusually
low BSCOE readmission rates reflect unmeasured variables
such as surgical experience, and those with high rates of
readmission could be indicative of either surgeon inexperience,
case difficulty, or surgeon preference for open procedures. Data
entered into BOLD is self-reported by BSCOE, so post-
discharge events are potentially underreported in the database,
though our selection of centers with high follow-up rates was
undertaken to offset potential underreporting in the larger
database.
Finally, the observational nature of the study precludes causal
inference about risk factors. Given that examination of factors
influencing relatively rare events like readmissions requires
thousands of patients to be adequately powered to assess
differences in risk, it is unlikely that randomized studies of these
factors will ever be performed. Therefore, decisions on patient
selection and risk calculations will inevitably be based on large
prospective observational databases like BOLD. Nested case-
control studies, in which more extensive collection of possible
explanatory variables is performed, may shed light on the problem
of unmeasured confounders in the BOLD dataset.
In conclusion, we have characterized patterns of risk for
readmission associated with patient and intraoperative factors for
the two most common bariatric procedures in the largest
prospective cohort of bariatric surgery patients to date. While
the overall readmission rates for both procedures are low, the
present results may prove to be an important clinical tool in the
development of patient education programs, algorithms for
procedure selection, and follow-up plans. In an effort to maximize
patient benefit and cost-effectiveness of bariatric surgery and to
reduce penalties from payers, primary care providers and surgeons
should understand patient-specific risks to optimize clinical care
for patients when both selecting for and immediately following
their bariatric operation.
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